Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apotea AB (publ)CHIX:APOTES 18 Earnings per Share (Diluted) is kr2.36 as of Jun. 2026. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 506 Healthcare Providers & Services companies, Apotea AB (publ) ranks better than 96.84% on this metric.
Apotea AB (publ)'s EPS (Basic) for the
three
months ended in Jun. 2026 was kr0.78.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.36.
During the past 12 months, Apotea AB (publ)'s average EPS without NRIGrowth Rate was -1.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 96.50% per year.
During the past 5 years, Apotea AB (publ)'s highest 3-Year average EPS without NRI Growth Rate was 96.50% per year. The lowest was 27.50% per year. And the median was 62.00% per year.
Apotea AB (publ) (CHIX:APOTEs) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Apotea AB (publ) Earnings per Share (Diluted) Related Terms
Apotea AB (publ) Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Apotea AB (publ)'s Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apotea AB (publ) Earnings per Share (Diluted) Chart
Apotea AB (publ) Earnings per Share (Diluted) Competitor Comparison
For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apotea AB (publ) PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s PE Ratio distribution charts can be found below:
* The bar in red indicates where Apotea AB (publ)'s PE Ratio falls into.
Apotea AB (publ) Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Apotea AB (publ)'s Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.36
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr2.36 mean?
Apotea AB (publ) (CHIX:APOTES) has a Earnings per Share (Diluted) of kr2.36 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Apotea AB (publ) and its competitors. According to the industry distribution chart, Apotea AB (publ) ranks #16 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 3.2%.
Is Apotea AB (publ)'s Earnings per Share (Diluted) too high?
Apotea AB (publ)'s current Earnings per Share (Diluted) is kr2.36. Based on the distribution chart, Apotea AB (publ) ranks #16 out of 506 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Earnings per Share (Diluted) compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Apotea AB (publ) ranks #16 out of 506 companies for Earnings per Share (Diluted). This places Apotea AB (publ) in the top 3% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 11.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Healthcare Providers & Services company?
The median Earnings per Share (Diluted) among Healthcare Providers & Services companies is 11.05, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Apotea AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Earnings per Share (Diluted) is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apotea AB (publ)'s current Earnings per Share (Diluted) is kr2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current Earnings per Share (Diluted) of kr2.36. The current Earnings per Share (Diluted) is kr2.36. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current Earnings per Share (Diluted) is kr2.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score
Get the complete analysis for CHIX:APOTES
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:APOTES has been successfully added to your 
